Pancreatic Cancer
Eir Biotherapies S.r.l. is involved in clinical research for pancreatic adenocarcinoma, with attention to locally advanced, non-resectable pancreatic cancer and ductal adenocarcinoma of the pancreas.
- Locally advanced pancreatic adenocarcinoma
- Non-resectable pancreatic cancer
- Ductal adenocarcinoma of the pancreas
The sponsor’s research activity is centered on therapeutic options for patients with limited surgical treatment possibilities in advanced pancreatic disease.
Cell-Based Gene Therapy
The sponsor’s trial portfolio includes cell-based gene therapy approaches designed for direct application within pancreatic tumour tissue, reflecting interest in advanced biologic therapies for solid tumours.
- Cell therapy
- Gene therapy
- Intratumoral treatment
This area highlights a focus on therapeutic strategies that combine biological engineering with localized delivery in cancer care.
Oncology Combination Therapy
Clinical interest also extends to the use of investigational therapies alongside established chemotherapy for pancreatic cancer, with emphasis on treatment settings where standard options remain limited.
- Combination therapy
- Standard-of-care chemotherapy
- Solid tumour oncology
The sponsor’s work is positioned around refining treatment choices for complex pancreatic malignancies.
Image-Guided Local Administration
The funded research includes ultrasound-guided injections for direct tumour delivery, indicating therapeutic interest in image-guided local administration methods for oncology.
- Ultrasound guidance
- Local tumour delivery
- Interventional oncology
This area supports the sponsor’s focus on targeted administration techniques within pancreatic cancer treatment.
